Cannabis Law Report

DECEMBER 3, 2021

We are honored to be at the AES Meeting this year after almost a year of planning from our medical and scientific affairs, clinical, and advocacy teams, with nine presentations spanning our IV and oral portfolio—Marinus’ largest data showing to date,” said Scott Braunstein, M.D., Chief Executive Officer of Marinus Pharmaceuticals. “We

Epilepsy 52

Epilepsy Pharmaceutical Data Clinical Trials 52

Cannabis Law Report

MAY 26, 2022

Successful Behavioral Addiction Study Supplied Data for Patent. The successful completion of Awakn’s behavioral addictions study was announced last week and the data provided from the study was used in the patent filing. The treatment was also well tolerated with no safety concerns. Awakn Life Sciences Corp. (

Treatment 52

Treatment Research and Development Therapy Data 52

Medicinal Genomics

JULY 14, 2022

The truth is that total count tests are not a good indicator of cannabis and hemp product safety for the following reasons: Pathogenic microbes may still be present Testing methods often do not agree Growers are discouraged from using beneficial microbes Growers are encouraged to use remediation. fumigatus, A.

Safety 92

Safety Research and Development Concentrates Food 92

Cannabis Law Report

AUGUST 10, 2021

We are delighted by today’s decision from the MHRA for this new indication, which represents a significant step forward for TSC patients in the UK, many of whom may benefit from this new treatment,” said Chris Tovey , Executive Vice President, Chief Operating Officer and Managing Director, Europe & International at Jazz Pharmaceuticals.

Pharmaceutical 98

Pharmaceutical Treatment Epilepsy Research and Development 98

Cannabis Law Report

JULY 28, 2021

Validates Cepharanthine’s potential in treating various cancers with unsatisfactory treatment options. Additionally, there were several instances in which cepharanthine displayed growth inhibition which was comparable or superior to current gold standard treatments, including colorectal, liver and skin cancers.

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

Cannabis Law Report

DECEMBER 7, 2021

Despite the increased use of medical cannabinoids, the efficacy and safety of the treatment among children remain uncertain. The objective was to study the efficacy and safety of medical cannabinoids in children. Adverse mental events were reported as well, however, more research should be performed to assess well this outcome.

Safety 52

Safety Cannabinoids Events Data 52

Cannabis Law Report

MAY 29, 2022

Earlier this month, Senators Brian Schatz (D-HI) and Cory Booker (D-NJ) sent a letter to the National Institutes of Health (NIH) and the Food and Drug Administration (FDA) urging both agencies to advance research on the therapeutic effects of psychedelic drugs. [1] Recent Regulatory Developments. Challenges.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Cannabis Law Report

DECEMBER 26, 2021

The patent relates to improved technology for detection and maintenance of the optimal therapeutic psychedelic state, which Entheon intends to study through the monitoring of electroencephalogram (EEG) biomarkers in order to optimize the treatment of neuropsychiatric conditions. ” In Vivo Toxicity Assays Completed.

Research and Development 52

Research and Development Clinical Trials Treatment Packaging 52

Veriheal

APRIL 11, 2022

federal government is granting a handful of American companies the option to cultivate and study cannabis for medical research purposes. Groff North America is proud to be producing research-grade marijuana, so we can continue growing the field of cannabis-based medicine,” reads an official statement from the company’s website.

Pharmaceutical 104

Pharmaceutical Research and Development DEA Clinical Trials 104

Cannabis Law Report

SEPTEMBER 23, 2021

This Was the World’s First Published Study Assessing MDMA-Assisted Psychotherapy as a Treatment for Addiction. BIMA was an Open-label safety, tolerability and proof-of-concept study to investigate the role of MDMA-Assisted Psychotherapy in treating patients with alcohol use disorder (AUD). Treatment of AUD rates are low at 16%.

Research and Development 52

Research and Development Therapy Treatment Data 52

Cannabis Law Report

JANUARY 31, 2022

TSX-V:NUMI, OTC:LKYSF) said that its research facility– Numinus Bioscience– has been included on Health Canada’s list of federally licensed psilocybin producers. This list is available by request to those seeking access to psilocybin through the Special Access Program (SAP), and clinical researchers. Numinus Wellness Inc.

Research and Development 52

Research and Development Clinical Trials Packaging Access 52

SpeedWeed

FEBRUARY 21, 2021

GBS’s CCCM were developed to reduce high levels of specific cytokines and pro-inflammatory processes triggered by the virus as part of the body’s defences. If successful, data from (Kaminski’s) pre-clinical study would be used as part of the support for an Independent New Drug filing with the FDA,” said Small-Howard.

Treatment 52

Treatment Research and Development Cannabinoids Data 52

Veriheal

SEPTEMBER 16, 2022

Recent research has found that aerosolized cannabis can provide long-term pain reduction, specifically in patients with neuropathy and other chronic conditions. One team of researchers made use of an innovative, novel inhalation device called the Syqe Inhaler to investigate the efficacy of cannabis for neuropathic pain.

Patients 120

Patients Chronic Pain Research and Development Treatment 120

Veriheal

NOVEMBER 21, 2023

Scientific research supports the potential of cannabinoids in regulating blood sugar levels, weight management, and addressing diabetic neuropathy. Quemarr’s transformative approach to diabetes treatment offers patients a less intrusive alternative to conventional insulin treatments.

Research and Development 106

Research and Development Consumption Education Data 106

Veriheal

SEPTEMBER 23, 2021

Note: Veriheal does not support illegally consuming therapeutic substances such as Iboga but acknowledges that it transpires because of the current illicit status, which we strive to change by advocating for research, legal access, and responsible consumption. Is There Any Research on Iboga and Its Medicinal Properties?

Treatment 98

Treatment Medicine Research and Development Therapy 98

Cannabis Law Report

NOVEMBER 22, 2019

MMJ International Holdings, the premier medical cannabis research company, announced that it has received DEA approval to ship THC and CBD from Canada. MMJ International Holdings is developing oral drug products from natural whole plant extract derivatives from the marijuana plant containing THC and CBD. Orphan Drug Designation?

DEA 66

DEA Clinical Trials THC Research and Development 66

Cannabis Law Report

JUNE 16, 2021

Both parties to this new relationship are committed to excellence in clinical research and patient access to psychedelic medicine with a focus on naturally derived psilocybin. As two emergent complementary medicines, many parallels exist between the medical cannabis industry and the currently developing psychedelic medicine industry.

Clinical Trials 104

Clinical Trials Therapy Research and Development Events 104

Cannabis Law Report

DECEMBER 9, 2021

The study flagship site will be at John Hopkins University (JHU) with research led by Dr. Matthew Johnson. The study involved 100 treatment-resistant patients and were randomized to psilocybin or the nicotine patch, each receiving the same cognitive-behavioral therapy. DENVER, Dec.

Clinical Trials 52

Clinical Trials Research and Development Treatment Therapy 52

MMJ Recs

NOVEMBER 17, 2023

By legalizing MMJ, the state has facilitated access to a natural and potentially life-changing treatment option for patients suffering from various medical conditions. Support for Patient Well-Being The availability of medical marijuana in local communities fosters an environment of support for patients seeking alternative treatments.

Chronic Pain 98

Chronic Pain Therapy Research and Development Treatment 98

Cannabis Law Report

AUGUST 27, 2021

The Board will advise Delic and its subsidiaries, including Ketamine Infusion Centers, Delic Labs and others, as they develop safety protocols and best practices pertaining to legal psychedelic wellness treatments today and those legalized in the future. About Delic Corp, Inc.

Research and Development 98

Research and Development Treatment Media Medicine 98

MMJ Recs

MARCH 16, 2024

With increasing acceptance of medical marijuana as a legitimate treatment option for various health conditions, the industry has attracted significant attention from investors, entrepreneurs, and policymakers alike. Policy decisions related to taxation, zoning, and advertising also impact the industry’s operations and growth trajectory.

Supply Chain 105

Supply Chain Research and Development Marijuana Seed-To-Sale 105

Cannabis Law Report

JUNE 1, 2021

The initial shipment is designated to be used by the Clinic in a pilot run in preparation for the previously announced study , based out of the United Kingdom, on the safety and efficacy of cannabis and hemp for the treatment of patients suffering from chronic pain. billion, servicing nearly 340,000 active patients. RYAH Group, Inc.

Clinical Trials 89

Clinical Trials Chronic Pain Data Research and Development 89

Cannabis Law Report

JUNE 19, 2022

Beckley Psytech aims to track and improve patient experience through an integrated, digitally-assisted treatment model. This latest partnership further strengthens Beckley Psytech’s digital strategy to develop personalised, end-to-end treatment programmes for patients in areas of significant unmet medical need. About 5-MeO-DMT.

Clinical Trials 52

Clinical Trials Patients Research and Development Treatment 52

Puff Puff Post

DECEMBER 28, 2018

An official study is aimed to conclude in July of 2019, where we’ll see all the data which comes forth. The Current Treatments for Autism. Most education-based autism treatment is focused on teaching developing children self-care, communicative, and social skills. Instead, CBD is being used.

Treatment 76

Treatment Oil CBD Therapy 76

Veriheal

JUNE 30, 2023

A study investigated psilocybin’s effect on alcohol addiction, the FDA outlined best practices for future psychedelic research, and the NCAA is inching toward cannabis policy change. For their analysis, researchers conducted qualitative interviews with 13 individuals who had participated in a psilocybin clinical trial.

Clinical Trials 98

Clinical Trials Research and Development Therapy Policy 98

Veriheal

AUGUST 7, 2022

New data published in the Journal of Cannabis Research claims that almost one in two authorized medical cannabis patients in Canada managed to either completely stop or reduce their intake of controlled substances, such as alcohol and opioids , by using cannabis. As of 2020, the market was worth CAD $2.6 billion (USD $2 billion).

Consumption 109

Consumption Patients Research and Development Data 109

The Cannigma

FEBRUARY 2, 2021

In light of these results, the researchers behind the survey say that physicians should pay special consideration to these aspects when advising patients on their medical cannabis treatment options. Physicians should consider these aspects when advising their patients about treatment with medicinal cannabis.

Patients 87

Patients Clinical Trials Research and Development Treatment 87

Cannabis Law Report

OCTOBER 22, 2021

–The Company expects to hold a Research & Development event to review,these breakthrough findings in Q4 2021 that will be open to the public, shareholders, analysts and the media– TORONTO, CANADA – October 19, 2021 – Cybin Inc. About Cybin.

Research and Development 52

Research and Development Safety Media Data 52

Cannabis Law Report

OCTOBER 29, 2019

ElleVet Sciences is pleased to announce the results and publication of the first safety study on the use of hemp CBD/CBDA. The 12-week safety study, conducted by Dr. Joseph Wakshlag, DVM, Ph.D., This data gives us confidence in the use of both the chew and the oils as effective means for delivering CBD to your pet.”.

Safety 45

Safety CBD Clinical Trials Oil 45

Cannabis Law Report

OCTOBER 29, 2021

Further strengthens the Company’s drug development pipeline of tryptamines by introducing novel psilocin analogues containing enhancements in safety and efficacy tailored for medical use. Mydecine Reports Successful Synthesis of Novel Tryptamine Improving the Pharmaceutical Properties of Psilocin. DENVER, Oct. DENVER, Oct.

Pharmaceutical 52

Pharmaceutical Research and Development Data Safety 52

Veriheal

DECEMBER 23, 2022

Researchers Inspected Cannabis Products for Contaminants. Dr. Maxwell’s team also collected data contained in samples sourced from California. Since cannabis products are being marketed “as alternative options to standard medical treatments,” the issue is particularly worrying. As per the results, 2.3%

Research and Development 92

Research and Development Agriculture Data Extraction 92

Cannabis Law Report

JANUARY 12, 2022

Through this collaboration, the NPA and Maya will offer both the education and the technology infrastructure needed to make this possible, ensuring accessibility and safety to all communities. “We The Maya platform empowers psychedelic researchers, providers, and participants to collectively chart psychedelic best practices.

Research and Development 52

Research and Development Therapy Safety Clinical Trials 52

Puff Puff Post

MARCH 10, 2020

“We are very pleased with the rapid completion of enrollment achieved by the team at the Centre for Human Drug Research (CHDR) in Leiden, the Netherlands,” said Alexandra Mancini, InMed’s Senior Vice President of Clinical Development & Regulatory Affairs. For more information, visit www.inmedpharma.com.

Clinical Trials 84

Clinical Trials Pharmaceutical Research and Development Cannabinoids 84

Cannabis Law Report

AUGUST 12, 2021

Highlights: Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021. Partnership being developed with leading UK institutions to accelerate psychedelic research and develop new models of mental health care in the UK.

Clinical Trials 98

Clinical Trials Therapy Research and Development Data 98

The Cannigma

AUGUST 22, 2021

First things first, there is very little we know scientifically about the actual efficacy of cannabis tampons specifically, although there is a growing body of research on how cannabis, CBD, and THC can help treat menstrual pain and various gynecological conditions. Do cannabis tampons work? More on that below.). Are CBD tampons safe?

THC 119

THC CBD Research and Development Conditions 119

Canna Law Blog

NOVEMBER 6, 2021

Once off-limits because of federal prohibition, a trickle of research from the 1990s has grown into a stream. But despite increasing acceptance by the public, and commercial investment in psychedelic therapies, aging federal laws stem the flow of vital research. Research was permitted in the mid-20th century, until the law stepped in.

Clinical Trials 98

Clinical Trials DEA Research and Development Therapy 98

Cannabis Law Report

JUNE 5, 2019

The Pharmaceutical Organization, Department of Medical Affairs, signed a joint research on standard quality medical marijuana extracts for patients with chemo-allergic cancer, epilepsy, muscle contraction in patients with deteriorating nerve sheaths. Effective, most effective in treatment Relieve symptoms. Today (30 May) at 09.30

Pharmaceutical 40

Pharmaceutical Extraction Epilepsy Research and Development 40